Symposium: Rapid Initiation of MOUD in Acute Care Settings: Findings from the SWIFT and ED-INNOVATION trials from the NIDA Clinical Trials Network (CTN)-Rapid Initiation of MOUD in Acute Care Settings: Findings from the SWIFT and ED-INNOVATION trials from the NIDA Clinical Trials Network (CTN)

Rapid Initiation of MOUD in Acute Care Settings: Findings from the SWIFT and ED-INNOVATION trials from the NIDA Clinical Trials Network (CTN)

Back to course

Video Transcription

Video Summary

The video transcript discusses the findings from various trials conducted by the NIDA Clinical Trials Network on the rapid initiation of medications for opioid use disorder (MOUD) in acute care settings. The panel of experts emphasizes the importance of bridging the gap between research and practice to improve substance use disorder treatment. They discuss barriers and facilitators to implementing MOUD in acute care and highlight strategies such as training and shared decision-making tools. The use of different medication formulations, including injectable buprenorphine, is also discussed in the context of the emergency department. The efficacy and safety of these formulations are highlighted, along with their potential to improve treatment engagement. The researchers also present findings from a study on the use of buprenorphine for opioid withdrawal in emergency departments and other clinical settings. They found that the risk of precipitated withdrawal was low and similar for patients who tested positive for fentanyl and those who did not. The use of adjunctive medications and individualized care is emphasized for a safe and effective transition to buprenorphine treatment. The panel concludes that buprenorphine is a valuable medication for individuals with opioid addiction and that clinicians should not be deterred from offering it due to concerns about precipitated withdrawal.

Keywords

NIDA Clinical Trials Network

rapid initiation of medications

opioid use disorder

MOUD

acute care settings

bridging the gap

research and practice

substance use disorder treatment

barriers and facilitators

implementing MOUD

injectable buprenorphine

emergency department

treatment engagement

buprenorphine for opioid withdrawal

adjunctive medications

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 108 East Providence, RI 02914 cmecpd@aaap.org Privacy	About Advocacy Membership Fellowship Education and Resources Training Events